Zydus Lifesciences reports that its U.S. office in New Jersey completes a U.S. Food and Drug Administration (USFDA) inspection of its pharmacovigilance and post-marketing surveillance system with “nil observations.” The company says the inspection result is based on an onsite review conducted by the USFDA.
Both outlets state that the inspection takes place from September 22 to September 25, 2026, and specifically focuses on the company’s pharmacovigilance and post-marketing surveillance processes. The reporting does not include any further findings, corrective actions, or regulatory concerns, and instead highlights the absence of observations.
In terms of context, the outlets both rely on the company’s public disclosures, while providing limited additional detail beyond the inspection scope, dates, and outcome. Aside from minor wording differences, the accounts align on what was inspected and that the USFDA records no observations following the visit.
